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Abstract
The study of the biology of evolution has been confined to laboratories and model organisms. However, controlled
laboratory conditions are unlikely to model variations in environments that influence selection in wild populations. Thus,
the study of ‘‘fitness’’ for survival and the genetics that influence this are best carried out in the field and in matching
environments. Therefore, we studied highland populations in their native environments, to learn how they cope with
ambient hypoxia. The Andeans, African highlanders and Himalayans have adapted differently to their hostile
environment. Chronic mountain sickness (CMS), a loss of adaptation to altitude, is common in the Andes, occasionally
found in the Himalayas; and absent from the East African altitude plateau. We compared molecular signatures (distinct
patterns of gene expression) of hypoxia-related genes, in white blood cells (WBC) from Andeans with (n=10), without CMS
(n=10) and sea-level controls from Lima (n=20) with those obtained from CMS (n=8) and controls (n=5) Ladakhi subjects
from the Tibetan altitude plateau. We further analyzed the expression of a subset of these genes in Ethiopian highlanders
(n=8). In all subjects, we performed the studies at their native altitude and after they were rendered normoxic. We
identified a gene that predicted CMS in Andeans and Himalayans (PDP2). After achieving normoxia, WBC gene expression
still distinguished Andean and Himalayan CMS subjects. Remarkably, analysis of the small subset of genes (n=8) studied in
all 3 highland populations showed normoxia induced gene expression changes in Andeans, but not in Ethiopians nor
Himalayan controls. This is consistent with physiologic studies in which Ethiopians and Himalayans show a lack of
responsiveness to hypoxia of the cerebral circulation and of the hypoxic ventilatory drive, and with the absence of CMS on
the East African altitude plateau.
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Introduction
The human genome was sequenced only recently, but already
the focus of much research has shifted to human genetic variation
and epigenomics has been selected as one of NIH’s Roadmaps
Initiative for 2008 [1] The discovery of numerous diseases
associated with DNA duplications and deletions, with single
nucleotide polymorphisms (SNPs), and with gene mutations has set
the stage for the analysis of the molecular underpinnings of
adaptation to life at high altitudes [2]. The genomic era has also
opened the way to studying the basis of susceptibility to chronic
mountain sickness (CMS), a disease of maladaptation to altitude
[3]. CMS has numerous parallels with diseases frequently
encountered at sea level in which hypoxia plays an important
PLoS ONE | www.plosone.org 1 June 2008 | Volume 3 | Issue 6 | e2342role, such as chronic obstructive pulmonary disease, sleep apnea
and cancer. Thus, lessons from the mountains might impact the
understanding and treatment of diseases at sea level.
More than 140 million people live and work at altitudes above
2500 m [4]. The three large high altitude populations are the
Andeans, the Himalayans and the lesser studied inhabitants of the
of East African high altitude plateau. These populations have
different phenotypes and different strategies for coping with their
inhospitable hypoxic environment [5,6]. However, their genotypes
and the molecular signatures (defined as a distinct pattern of gene
expression) that contribute to adaptation or maladaptation of these
people remain poorly understood [7].
All highlanders are exposed to high levels of free radicals and
oxidants [8]. These chemical species, byproducts of mitochondrial
metabolism, include the superoxides (O2
2), peroxides (H2O2) and
hydroxyl radicals (OH
2), and are collectively designated as
reactive oxygen species (ROS ). ROS have also been associated
with neurodegenerations such as Alzheimer’s disease, heart disease
and cancer, and they have been implicated in aging [9].
These molecules are also crucial for the maintenance of
homeostasis. The ROS are abundantly formed during hypoxia
and can serve as signaling molecules that help maintain
homeostasis. Specific proteins such as the guanosine 39,59-
monophosphate (cGMP)-dependent protein kinase PKG 1a
isoform, may in fact serve as direct ROS sensors [10].
Here we examine a set of hypoxia-related genes expressed in
white blood cells (WBC) in Andean highlanders born and living at
4338 m, both healthy subjects and patients suffering from CMS.
We also collected WBC from the same individuals after a short sea
level sojourn (in Lima, Peru at 150 m) and compared the gene
expression profiles with those from permanent sea level inhabitants
in Lima.
We studied Himalayan highlanders living at 4450 m. on the
Tibetan plateau; healthy natives from a village named Korzok and
their neighbors with CMS. Because of the difficulties in rapidly
getting people off the Tibetan plateau to low altitude we exposed
both group to hyperoxia for one hour at their native altitude. We
obtained WBC from this cohort before and after hyperoxia.
We conducted a parallel study, on a subset of the genes in
Ethiopian highlanders. We obtained two samples of WBC, one at
their resident altitude of 3622 m in the Simen Mountain National
Park and one within 24 hours of arrival in the Tekeze River Gorge
(794 m.). For genes studied, see Text S1.
Results
We examined differences in gene expression in high altitude
Peruvians with CMS and in healthy Peruvian high altitude
subjects who were free of symptoms and signs of CMS (CMS-sc of
,12, our normal high altitude controls in Peru). Expression levels
in these two Peruvian altitude-dwelling populations, at altitude and
after they were brought down to Lima, were then compared to
those in sea-level Peruvians at Lima. We next compared our
Peruvian results with those we obtained from Himalayan subjects
with and without CMS, in ambient air and after they were
rendered hyperoxic, with those from Ethiopians, a high altitude
population in whom CMS has not been reported. The
demographics of our Peruvian, Himalayan and Ethiopian study
groups are given in Table 1.
To assess the impact of specific genes on the CMS scores, using
a sliding scale of CMS-scores derived from both controls and CMS
patients, we constructed an ‘‘impact table’’ for the Cerro de Pasco
groups at altitude (Table 2) and in Lima Table 3.
A linear regression model shows that the best predictor of CMS
(highlighted in the tables) in this population is the expression of
PDP2, a gene encoding a protein phosphatase that de-phosphor-
ylates the E1-alpha subunit of pyruvate dehydrogenase and thus
promotes pyruvate entry into the Krebs cycle. Adjusting for PDP2
eliminates the impact of the other genes on the CMS-sc (columns,
ADJ for PDP2). However, adjusting for each of the remaining
genes strengthens the impact of PDP2 (columns, Adj. PDP2). This
supports the importance of PDP2 in predicting CMS.
We constructed a similar impact table for our Himalayan
subjects (Table 4) while at their resident altitude breathing
ambient air. The best predictor of CMS in a linear regression
model in the Himalayas is also PDP2. However, after 1 hour of
hyperoxia, at the same altitude, the best predictor of CMS is
PDK4 (Table 5).
We further refined our analyses by constructing scatter plots,
‘‘niche’’ graphs, using genes that best explained the presence of
CMS in a logistic regression analysis. We show the difference in
gene expression between the 3 study groups in Lima and the 2 in
Cerro de Pasco. In ambient normoxia of Lima, there was complete
separation of the patients with CMS from the altitude controls as
seen in the niche graphs. The controls, high-altitude and sea-level
Lima natives, were indistinguishable in Lima. In their native
altitude environment, however, the controls and CMS patients
showed slight overlap of the niche graphs (Fig. 1).
A similar analysis of our Himalayan cohort (Fig. 2) showed good
separation in ambient hypoxia but the CMS patients were less well
separated from controls in induced normoxia.
Quantitative comparisons of gene expressions of Andean and
Himalayan subjects are shown in Fig. 3. All Himalayans (CMS
patients and controls) had significantly higher expression levels of
the genes analyzed (except for HPH1) than Andeans living at
similar altitude.
Table 1. Demographics of our study populations. (mean6SD).
ETH. HIGH PERU CONTR. HIGH ETH. LOW
PERU CONTR.
LOW
HIMALAYAN CONTR.
AMBIENT
HIMALAYAN CONTR.
HYPEROXIA.
AGE 35.5641 37.166.7 ….. ….. 42.169.4 ……
O2 SAT 8863.21 91.461.9* 96.761.4 99.960.3 81.864.4 98.260.7
PetCO2(mm.Hg) 37.162.31 31.863.51** 47.164.41 39.362.21 29.963.7 NA
CMS-score 0.360.51 1.361.61 NA NA 8.263.4 NA
Hematocrit % 48.564.61 54.662.41{ NA 53.664.6 54.165.7{ NA
Values are reported either at high altitude (HIGH), or low altitude (LOW) in Peru and Ethiopia. The Himalayans were studied at the same altitude in ambient air (ambient)
and after 1 hour of hyperoxia.
1 From reference [22].
{P=0.004.
*P=0.02.
**P,0.01 compared to Ethiopians. ……..=no change; NA=not done.
doi:10.1371/journal.pone.0002342.t001
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the Andes and Himalayas is shown in Fig. 4. Both populations
were scored using an internationally accepted scoring system
devised for the high Andes [11].
We examined a small subset of genes (n=8) in our eight
Ethiopian subjects. Most gene expressions were several orders of
magnitude higher in Ethiopians than in Andeans and Himalayans
at altitude. Remarkably, normoxia in the Tekeze River Gorge
(794 m.) in Ethiopians, or normoxia in Himalayan controls had no
effect on expression levels except for PDP1 which was significantly
upregulated in normoxia (P,0.04). By contrast, in Peruvians, in
Lima (normoxia), significant increases were found, except for
HPH1, HPH2 and EPO which were down regulated (Fig. 5).
Importantly, features of hypoxia-adapted tissues, such as up-
regulation of enzymes related to ‘‘aerobic glycolysis’’ favoring
lactate accumulation in the presence of hypoxia and reducing
ROS formation (PDK1, PDK2), were significantly higher in
Ethiopians in hypoxia than in Peruvians in their native hypoxic
environment, suggesting that Andean tissues were poorly adapted
to ambient hypoxia.
Genes involved in erythropoiesis were highly expressed in
Ethiopians at altitude, and remained significantly higher in
Ethiopians in normoxia (EPOR, EPO).
Vascular endothelial growth factor C (VEGFC), involved in
blood vessel proliferation in response to hypoxia, was very high in
Ethiopians at altitude and in the normoxic environment of the
Gorge, but was significantly lower in Andeans and Himalayans at
altitude. Unfortunately, it was not assayed in Peruvian samples at
Lima. This is consistent with the view that blood vessel
proliferation is an important strategy in Ethiopian adaptation,
insuring better blood flow to tissues and consequently better
oxygen delivery.
Table 2. Impact table to show the predicting power of
specific hypoxia-related genes on CMS (CMS-score$12) in our
Andean subjects in Cerro de Pasco, Peru, altitude 4338 m.
HIGH CERRO A
ADJ. for
PDP2
Adj.
PDP2
GENES STB P STB P STB P
lg_EPO 0.05 0.82 0.09 0.66 20.56 0.012
lg_HPH1 20.02 0.94 20.04 0.85 20.56 0.013
lg_HPH2 20.04 0.85 20.01 0.95 20.56 0.013
lg_HPH3 0.24 0.30 0.44 0.03 20.69 0.002
lg_VEGFC 20.05 0.83 0.33 0.16 20.73 0.005
lg_PDK1 20.19 0.42 0.00 0.11 20.56 0.019
lg_PDP1 20.43 0.05 20.03 0.93 20.54 0.101
lg_HIF1A 0.01 0.95 0.21 0.32 20.62 0.008
lg_HIF1B 20.18 0.45 0.28 0.28 20.73 0.009
lg_HIF2A 20.37 0.11 20.10 0.7 20.51 0.048
lg_HIF3A 20.28 0.24 0.16 0.56 20.66 0.023
lg_PDK2 20.45 0.05 20.16 0.54 20.46 0.095
lg_PDP2 20.56 0.01 ……… …
lg_PDK3 20.50 0.02 20.27 0.3 20.40 0.12
lg_PDK4 20.39 0.09 20.13 0.6 20.49 0.053
lg_PDHE1A1 20.28 0.23 0.20 0.7 20.70 0.021
lg_GAPDH 0.17 0.46 0.17 0.41 20.55 0.012
lg_EPOR 0.12 0.62 0.29 0.15 20.64 0.005
lg_GLUT1 0.04 0.86 0.10 0.64 20.57 0.012
lg_LDHA MISSING
lg_CATD MISSING
To assess the impact of specific genes on chronic mountain sickness-score
(CMS-sc), using a sliding scale (continuous), we constructed an ‘‘impact table’’
for the combined (CMS & Controls) Cerro de Pasco groups at altitude (A).
In univariate linear regression model, PDP2 is found to be the most significant
predictor of CMS-sc (highlighted). Adjusting for PDP2 eliminates the impact of
the other genes on the CMS-sc (columns, ADJ for PDP2). However, adjusting
PDP2 for each of the remaining genes, assayed here, strengthens the impact of
PDP2 (columns, Adj. PDP2).
This supports the importance of PDP2 in predicting CMS-sc.
PDP2 is the phosphatase that de-phosphorylates the E1-alpha subunit of
pyruvate dehydrogenase which promotes pyruvate entry into the Krebs cycle,
The STB is the standardized estimate for the parameter estimate of an
explanatory variable in the logistic regression model and is computed by
multiplying the estimate by the sample standard deviation for the explanatory
variable and dividing by p/!3 [Ref. SAS 9.1; On Line Help] (For glossary of terms
see Text S1).
doi:10.1371/journal.pone.0002342.t002
Table 3. Impact table to show the predicting power of
specific hypoxia-related genes on CMS (CMS-score$12) in our
Andean subjects in Lima, Peru, altitude 150 m.
LOW LIMA B
ADJ. for
PDP2
Adj.
PDP2
GENES STB P STB P STB P
lg_EPO 20.28 0.23 0.02 0.91 20.73 ,0.0001
lg_HPH1 20.28 0.27 20.17 0.36 20.68 0.002
lg_HPH2 20.12 0.63 0.21 0.25 20.81 ,0.0004
lg_HPH3 20.16 0.64 0.18 0.44 20.87 0.004
lg_VEGFC MISSING
lg_PDK1 20.60 0.005 20.32 0.08 20.56 0.005
lg_PDP1 20.37 0.11 20.10 0.6 20.69 0.001
lg_HIF1A 20.21 0.34 20.02 0.9 20.72 ,0.0004
lg_HIF1B 20.31 0.18 0.12 0.6 20.79 ,0.0004
lg_HIF2A 20.50 0.02 20.05 0.81 20.69 0.006
lg_HIF3A 20.28 0.27 20.17 0.36 20.68 0.002
lg_PDK2 20.37 0.11 20.17 0.35 20.68 0.001
lg_PDP2 20.73 0.0003 …… ……
lg_PDK3 20.45 0.05 20.12 0.55 20.67 0.003
lg_PDK4 0.21 0.38 0.12 0.46 20.71 ,0.0004
lg_PDHE1A1 20.67 0.001 20.35 0.1 20.51 0.021
lg_GAPDH 20.16 0.65 0.18 0.44 20.87 0.004
lg_EPOR 20.36 0.12 0.01 0.95 20.73 0.002
lg_GLUT1 MISSING
lg_LDHA 20.69 0.0008 20.37 0.08 20.48 0.03
lg_CATD 20.49 0.03 20.15 0.44 20.65 0.004
To assess the impact of specific genes on chronic mountain sickness-score
(CMS-sc), using a sliding scale (continuous), we constructed an ‘‘impact table’’
for the combined (CMS & Controls) Cerro de Pasco groups while normoxic in
Lima (sea level) (B).
In univariate linear regression model, PDP2 is found to be the most significant
predictor of CMS-sc (highlighted) even in normoxia. Adjusting for PDP2
eliminates the impact of the other genes on the CMS-sc (columns, ADJ for
PDP2). However, adjusting PDP2 for each of the remaining genes, assayed here,
strengthens the impact of PDP2 (columns, Adj. PDP2). This supports the
importance of PDP2 in predicting the CMS-scores of our subjects while in Cerro
de Pasco at altitude. (For glossary of terms see table 2 and Text S1).
doi:10.1371/journal.pone.0002342.t003
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PLoS ONE | www.plosone.org 3 June 2008 | Volume 3 | Issue 6 | e2342Taken together these WBC gene-expression results give insight
into the different ways in which Peruvians, Ethiopians and
Himalayan highlanders adapt to life in chronic hypoxia.
Discussion
The understanding of evolution depends on discerning the
causes of variations among individuals which impact the fitness of
future generations and its genetic basis.
The study of the biology of evolution is often confined to the
laboratory and to model organisms. However, laboratory
conditions, though offering advantages, are unlikely to accurately
model the variations in environments that bear heavily on
selection in wild populations. Thus, the study of fitness and the
genetics that influence this are best carried out in matching
environments to which humans are adapted. There is, therefore,
great interest in transferring genomics to the field, away from the
laboratory [12].
How humans adapted to ambient hypoxia through changes in
the expression of hypoxia-related genes resembles a puzzle in
which most pieces are missing. Here we provide a few of the
missing pieces to strengthen the evidence that evolution over a
relatively short time span has lead to survival advantages in
Ethiopians, to a lesser extent in Himalayans, but not yet in
Andeans who arrived at their present abode at a later date.
The study of human biology in the mountains began about
2000 years ago with a description by a Chinese official who wrote
of a high-altitude traveler: ‘‘His face turns pale, his head aches and
he begins to vomit’’ [13]. The Jesuit Jose ´ de Acosta, a sixteenth
century traveler in the Andes of Peru, was the first to attribute his
discomfort, when reaching an altitude of 4802 meters, to the ‘‘thin
air’’ [14].
Subsequently, numerous physiologic studies attempted to
explain the effects of ambient hypoxia on humans, and prepare
those who traveled to the mountains, not of necessity, but for
pleasure and sport.
The strategy of field studies at altitude was inaugurated by T. H.
Ravenhill who was the first to recognize in 1913, in a high altitude
mining camp in Chile, the occurrence of acute mountain sickness,
high altitude cerebral edema and high altitude pulmonary edema
[15]. The first to describe chronic mountain sickness, as distinct
from Ravenhill’s acute mountain sickness, was Carlos Monge of
Lima, Peru, who documented this affliction in 1928 in a native
miner from Cerro de Pasco and continued to study chronic
mountain sickness throughout his life [16]. The syndrome is
characterized by widespread dysfunction attributed to severe
hypoxia, especially during sleep, by accelerated aging and
neurologic signs such as a decreased hypoxic ventilatory drive
and a mild peripheral neuropathy [3,17]
We have presented, for the first time, a comparison of hypoxia
related gene expressions in WBC, in the three major high altitude
populations, Andeans, Ethiopians and Himalayans, collected from
the same individuals first in their native ambient hypoxia and then
while normoxic. Previous population based studies, using physi-
Table 4. Impact table to show the predicting power of specific hypoxia-related genes on CMS (CMS-score$12) in the Himalayas.
(Korzok village altitude 4450 m.).
In Himalayas Adjust for PDP2 Adjust PDP2
A STB P STB P STB P
PDK1 20.42 0.18 PDK1 0.19 0.74 PDP2 20.70 0.23
PDK2 0.14 0.67 PDK2 0.51 0.09 PDP2 20.79 0.02
PDK3 20.39 0.21 PDK3 0.43 0.48 PDP2 20.92 0.15
PDK4 0.24 0.46 PDK4 0.37 0.19 PDP2 20.62 0.04
PDP1 20.34 0.28 PDP1 20.07 0.84 PDP2 20.51 0.16
PDP2 20.54 0.07 …… … …
PDHE1a1 20.26 0.41 PDHE1a1 0.42 0.35 PDP2 20.87 0.07
HIF1a 0.29 0.36 HIF1a 0.57 0.04 PDP2 20.75 0.01
HIF1b 0.16 0.62 HIF1b 0.87 0.00 PDP2 21.10 0.00
HIF2a 20.02 0.96 HIF2a 0.64 0.07 PDP2 20.97 0.01
HIF3a 20.04 0.89 HIF3a 0.54 0.13 PDP2 20.89 0.02
HPH1 0.09 0.78 HPH1 0.41 0.18 PDP2 20.73 0.03
HPH2 20.25 0.43 HPH2 0.09 0.79 PDP2 20.60 0.12
HPH3 0.37 0.24 HPH3 0.18 0.55 PDP2 20.47 0.15
VEGF_R2 20.26 0.42 VEGF_R2 0.22 0.58 PDP2 20.69 0.10
EPOS 0.50 0.10 EPOS 0.55 0.03 PDP2 20.59 0.02
CAT_D 0.20 0.54 CAT_D 0.40 0.16 PDP2 20.66 0.03
GLUT1 0.20 0.54 GLUT1 0.38 0.18 PDP2 20.65 0.03
GAPDH 0.32 0.32 GAPDH 0.35 0.20 PDP1 20.57 0.05
GAPDH 0.32 0.32 GAPDH 0.35 0.20 PDP2 20.57 0.05
To assess the impact of specific genes on chronic mountain sickness-score (CMS-sc), using a sliding scale (continuous), we show an ‘‘impact table’’ for the combined
(CMS & Controls) Himalayan (Ladakh) groups at native altitude (A).
In univariate linear regression model, PDP2 is found to be the most significant predictor of CMS-sc (highlighted). Adjusting for PDP2 eliminates the impact of the other
genes on the CMS-sc (columns, ADJ for PDP2). However, adjusting PDP2 for each of the remaining genes, assayed here, strengthens the impact of PDP2 (columns, Adj.
PDP2). This supports the importance of PDP2 in predicting CMS-sc in the Himalayas just as in the Andes (For glossary of terms, see table 2 and Text S1).
doi:10.1371/journal.pone.0002342.t004
Hypoxia Mountains
PLoS ONE | www.plosone.org 4 June 2008 | Volume 3 | Issue 6 | e2342ologic measurements, have hinted at differences in human
adaptive strategies encountered in the Andes, Himalayas and the
East African high altitude plateau [6].
We first set out to uncover the molecular signature, defined here
as a distinct pattern of gene expression, that underlies the frequent
occurrence of CMS, a maladaptation syndrome in the Andes. We
found that PDP2, a phosphatase that de-phophorylates the E1
alpha subunit of pyruvate dehydrogenase and promotes pyruvate
entry into the Krebs cycle, is the best predictor of CMS. Low
expression of mRNA encoding this enzyme may be a marker of
chronic mountain sickness. We found, additionally, that in Cerro
de Pasco, altitude 4338 m, where the molecular signatures of both
study groups were influenced by the prevailing hypoxia, the CMS
patients remained distinguishable from control highlanders (Fig 1).
The prevailing opinion that CMS is rare in Tibetans [18] was
not borne out by our experience in Ladakh. We found, applying
the CMS-scoring system developed for Andeans in Korzok, a
village on the Tibetan plateau, situated at 4450 m., a surprisingly
large number of subjects with CMS. The prevalence of the various
symptoms and signs making up the CMS scores in the Himalayas
was significantly different, however, from that found earlier in the
Andes Fig. 4. This suggests that a better scoring system specifically
developed for the Himalayas might uncover other populations
living on the Tibetan plateau with comparable prevalence of CMS
to that in the Andes.
The molecular signature of CMS in the Himalayas is
surprisingly similar to that found in the Andes. Here too, PDP2
expression is the best predictor of CMS in ambient hypoxia
(Fig. 2.). This underscores the robustness of our analyses in 2
continents and implies that CMS has a molecular signature that is,
to some extent, dependent of genetic background. Both, Andeans
and Himalayans are likely to have descended from the same
ancestral population that migrated from Asia across ancient
Beringea to the New World [19].
Homeostasis, the ability to maintain a steady state in the face of
stress, is a fundamental property of life which presumably bestows
evolutionary advantages to those who face life at altitude and its
attendant, inescapable, hypoxic stress.
The low expression of mRNA encoding PDP2 in CMS patients
but not in controls living at the same altitude in the Andes and
Himalayas suggests that CMS represents a derangement in
molecular homeostasis, with inadequate up-regulation of hypox-
ia-related genes to maintain a steady state in the face of hypoxic
stress.
On the other hand, comparison of highland controls with Lima
controls in Lima, where both groups were shown to be normoxic,
revealed no differences in molecular signatures between these
study groups (Fig 1). This supports the notion that our highland
controls had no homeostatic derangement when hypoxia was no
longer influencing their molecular signatures. These results were
also consistent with clinical studies in Peru that showed that all
symptoms and signs of CMS disappear after 2 months of sea level
sojourn [20].
Additionally, we examined molecular signatures in well-adapted
East-African subjects and compared them to our highland and sea
level subjects from Peru and Himalayan highlanders from the
Tibetan plateau. In these field studies the limitations of geography
precluded perfect matching of altitudes. Sea-level studies of the
Andeans were performed in Lima at 150 m. whereas Ethiopians
could only be brought down to an altitude of 794 m. in the Tekeze
River Gorge. Also because of the difficulties of descent to the
Gorge, the Ethiopians were studied after a much longer period of
normoxia compared to the Peruvians. Moreover, because of
similar constraints of geography, our subjects from Korzok village
on the Tibetan plateau in Ladakh, were studied in artificial
normoxia at their resident altitude of 4450 m. (Fig. 6)
Because of technical difficulties in East Africa and unavoidable
delays only minute quantities of Ethiopian RNA were available,
precluding the analysis of the entire set of genes examined in
Peruvians and Himalayans.
The Ethiopian altitude dwellers had higher expression of PDP1
in their home village than Andean and Himalayan highlanders
(Fig. 5). A change from hypoxia at altitude (88% saturation) to
normoxia (96% saturation) in the Tekeze river Gorge did further
increase the expression of this gene. All the other genes assayed at
both locations remained unaffected by normoxia in Ethiopians
and Himalayans (Fig 5). Thus, normal Tibetan plateau residents
have a similar lack of responsiveness of gene expressions when
Table 5. Impact table to show the predicting power of
specific hypoxia-related genes on CMS (CMS-score$12) in the
Himalayas (Korzok village altitude 4450 m.) after 1 hour of
hyperoxia.
Adjust
for PDK4
Adjust
PDK4
B STB P STB P STB P
PDK1 20.35 0.25 PDK1 20.18 0.50 PDK4 0.54 0.06
PDK2 0.06 0.86 PDK2 0.27 0.31 PDK4 0.68 0.02
PDK3 20.22 0.47 PDK3 20.17 0.51 PDK4 0.58 0.04
PDK4 0.60 0.03 PDK4 ……… … …
PDP1 20.42 0.15 PDP1 20.29 0.27 PDK4 0.52 0.06
PDP2 20.15 0.62 PDP2 20.12 0.66 PDK4 0.59 0.04
PDHE1a1 20.45 0.13 PDHE1a1 20.36 0.15 PDK4 0.54 0.04
HIF1a 20.39 0.19 HIF1a 20.49 0.04 PDK4 0.67 0.01
HIF1b 20.20 0.51 HIF1b 20.22 0.39 PDK4 0.60 0.03
HIF2a 20.58 0.04 HIF2a 20.46 0.07 PDK4 0.47 0.06
HIF3a 20.51 0.08 HIF3a 20.42 0.09 PDK4 0.52 0.04
HPH1 20.32 0.29 HPH1 20.31 0.22 PDK4 0.59 0.03
HPH2 20.28 0.35 HPH2 20.20 0.43 PDK4 0.57 0.05
HPH3 0.10 0.75 HPH3 20.19 0.51 PDK4 0.67 0.03
VEGF_R2 0.11 0.72 VEGF_R2 20.06 0.81 PDK4 0.61 0.04
EPOS 20.03 0.92 EPOS 20.04 0.86 PDK4 0.60 0.04
CAT_D 0.02 0.95 CAT_D 20.09 0.74 PDK4 0.61 0.04
GLUT1 20.25 0.42 GLUT1 20.22 0.38 PDK4 0.59 0.04
VEGF_C 20.08 0.79 VEGF_C 20.14 0.60 PDK4 0.61 0.04
GAPDH 20.14 0.65 GAPDH 20.10 0.69 PDK4 0.59 0.04
To assess the impact of specific genes on chronic mountain sickness-score
(CMS-sc), using a sliding scale (continuous), we show an ‘‘impact table’’ for the
combined (CMS & Controls) Himalayan (Ladakh) groups at native altitude after
1 hour of hyperoxia (B). The best predictor, under these circumstances, is
PDK4.
In univariate linear regression model, PDK4 is found to be the most significant
predictor of CMS-sc (highlighted). Adjusting for PDK4 eliminates the impact of
the other genes on the CMS-sc (columns, ADJ for PDK4). However, adjusting
PDK4 for each of the remaining genes, assayed here, strengthens the impact of
PDK4 (columns, Adj.PDK4). This supports the importance of PDK4 in predicting
CMS-sc in the Himalayas under conditions of hyperoxia just as in the Andes in
normoxia, see Table 3, (For glossary of terms, see table 2 and Text S1).
PDK4 (pyruvate dehydrogenase Kinase 4) is a kinase involved in ‘‘aerobic
glycolysis’’ (the Warburg effect). It supports a metabolic pattern seen in many
(but not all) hypoxia adapted tissues, also in cancer cells and activated immune
cells.
doi:10.1371/journal.pone.0002342.t005
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related genes), supporting the impression that Himalayan
highlanders occupy an intermediate niche in the ‘‘adaptive scale’’,
between Ethiopians (well adapted) and Andeans (least adapted).
Remarkably, the expression of most of the studied genes
remained higher in Ethiopians in the Gorge than in our sea level
Peruvian controls at Lima, except for PDK1. This is an enzyme
thought to play a crucial role in tissue adaptation to hypoxia [21].
Its low expression in altitude adapted Ethiopians and Himalayans
underscores their superior ability to cope with hypoxia, which may
obviate the need to up-regulate PDK1 when in their native
environment. (For glossary of terms see Text S1).
How might PDP2 expression levels protect against chronic
mountain sickness? Recent studies on hypoxic cells have identified
Figure 1. Niche (scatter) plots of genes that best predict the presence of CMS in Peruvian altitude dwellers. Because LDHA was not
assayed at altitude it was substituted by PDK3 which was highly correlated with LDHA. A: CMS vs CP Controls in Lima (normoxia). B: Lima Controls vs
CP Controls in Lima. C: CMS vs CP Controls in Cerro de Pasco (4338 m,). When hypoxia was shown to have been replaced by short sea level sojourn,
normoxia (A), the CMS patients were clearly separated from control altitude dwellers. B. There were no differences between altitude controls and
Lima controls in Lima. In Cerro de Pasco the CMS patients and controls were mostly separated by the ‘‘discriminator line’’. Discriminator line based on
discrimination of the two groups by logistic regression. CMS=chronic mountain sickness. LDHA=Lactate dehydrogenase A. PDK3=. Pyruvate
dehydrogenase Kinase3. This kinase is involved in ‘‘aerobic glycolysis’’ (the Warburg effect). It suports a metabolic pattern seen in many (but not all)
hypoxia adapted tissue, also in cancer cells and activated immune cells. PDP2=phosphatase that de-phosphorylates the E1-alpha subunit of pyruvate
dehydrogenase. CP=Cerro de Pasco altitude 4338 m. Cerro=Cerro de Pasco. Con=Andean controls. H=high altitude. L=Low altitude
doi:10.1371/journal.pone.0002342.g001
Figure 2. Niche (scatter) plots of genes that best predict the presence of CMS in Himalayan altitude dwellers. A. CMS vs Controls in
Himalayans (Ladakh) at native altitude and ambient conditions at 4450 m. and at the same altitude after 1 hour of hyperoxia (B). A. In Korzok village,
Ladakh, the CMS patients and controls were clearly separated by the ‘‘discriminator line’’. B. When ambient hypoxia was shown to have been replaced
by induced normoxia, the CMS patients were still separated from control altitude dwellers, although the best predictors for CMS had changed.
Discriminator line based on discrimination of the two groups by logistic regression. CMS=chronic mountain sickness. PDK4=. Pyruvate
dehydrogenase Kinase 4. This kinase is involved in ‘‘aerobic glycolysis’’ (the Warburg effect).It supports a metabolic pattern seen in many (but not all)
hypoxia adapted tissue, also in cancer cells and activated immune cells. PDP2=phosphatase that de-phosphorylates the E1-alpha subunit of pyruvate
dehydrogenase. HIF1a, HIF2a, HIF3a, HIF1b=Hypoxia Inducible Factors, composed of alpha and beta subunits. Only the alpha subunit protein levels
are regulated by oxygen. HIF1b is used as a dimerizing partner by all three HIF1a’s.
doi:10.1371/journal.pone.0002342.g002
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in ROS production and thus forestall ROS damage to cellular
proteins; also a damaging component of many hypoxia associated
diseases at sea level such as Alzheimer’s disease and other
neurodegenerations.
Amongst the most notable adaptations is increased expression of
PDK1 (PDH (pyruvate dehydrogenase) kinase 1) [21]. PDPs
reverse the activity of PDKs, which limit glucose oxidation despite
the presence of oxygen and maintain glycolysis. Thus the balance
of activity between PDPs and PDKs determines whether organs
oxidize glucose completely to CO2 and H2O, or whether they
display ‘‘aerobic glycolysis’’. Low PDP activity would favor aerobic
glycolysis with reduced production of CO2. Thus the balance
between hypoxic adaptation and CO2 mediated vasodilatation, to
improve blood flow and thus oxygen availability to tissues, may be
different in CMS patients.
The remarkable impact of PDP2 (tables 2, 3, 4) in predicting
high CMS-scores in the Andes and Himalayas suggests that
pyruvate metabolism which is critically influenced by PDP2 is
disturbed in this disease and strengthens the proposition that low
expression of some mitochondrial genes in response to hypoxia is
important in the pathogenesis of CMS[21].
The niche graphs clearly illustrate the different molecular
signatures of Andeans and Himalayans with and without CMS
(Figs. 1, 2). The implication is that CMS is not simply a clinical
manifestation of a homeostatic derangement but might signify that
this derangement is superimposed on a genetic predisposition to
this disease. CMS is known to be a disease of older men and post-
menopausal women, in whom years of chronic hypoxia may have
combined with an appropriate genetic background to precipitate
the disorder.
Although no systematic survey to detect CMS has been
conducted in Ethiopia, we and others have seen no evidence of
this disorder on the East African high altitude plateau [22]. Our
finding that at altitude, many genes examined here were expressed
at levels that were several orders of magnitude higher in
Ethiopians than in Peruvians supports earlier suggestions that
Ethiopians show a different and more effective pattern of
adaptation to life at altitude [6].
It is now recognized that one of the most important physiologic
adjustment in the face of hypoxia is an increase in blood flow to
tissues facilitated by vasodilatation [23]. One of the extensively
studied mechanisms involves the release of endothelial nitric oxide
synthase (eNOS) and the subsequent generation of NO. A failure
Figure 3. Quantitative comparisons of gene expression in Andean and Himalayan altitude dwellers. A. Controls in Peru altitude 4338 m.
and Himalyan controls, on the Tibetan plateau in Ladakh, India, altitude 4450 m. B. CMS patients at the same altitudes as in A in Peru and in the
Himalayas. C. Peruvian and Himalayan controls in normoxia. D. Peruvian and Himalayan CMS patients in normoxia. The genes compared in the 2
populations are: 1=HIF-1a; 2=HPH3; 3=HIF-3a; 4=VEGFC; 5=PDK4; 6=HIF2a; 7=PDP2; 8=PDK1; 9=PDHE1a1; 10=EPOR; 11=PDP1; 12=PDK3;
13=HIF1b; 14=PDK2; 15=GLUT1; 16=GAPDH; 17=HPH1; 18=EPO; 19=HPH2. Interrupted lines span across genes not assayed. In ambient
hypoxia all Himalayans (controls and CMS) had significantly higher gene expression when compared to Andeans except for HPH1. The differences
between the groups, while normoxic, were not significant. (C. D.).
doi:10.1371/journal.pone.0002342.g003
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maladaptation syndrome in mountaineers [24]. NO diffuses from
the endothelium to the vascular media activating guanylate cyclase
which produces guanosine 39 ,5 9-monophosphate (cGMP). cGMP
in turn activates protein kinase G (PKG) which is a key enzyme in
vasorelaxation [23]. H2O2 and other ROS are also vasoactive and
can modify other downstream vasorelaxants [10]. Thus, hypoxia
and its vasodilator consequences are also dependent, to some
extent, on ROS generation and on PKG1a.
In earlier studies, we examined the sensitivity of the cerebral
circulation to hypoxia in the same Ethiopian subjects [25]. In these
physiologic studies we found that the cerebral circulation of
Ethiopians was insensitive to hypoxia, unlike in Peruvian high
altitude dwellers, despite the responses of the cerebral circulation
to exogenous NO donors being greater at altitude when compared
to Peruvians, implying enhanced vasodilatation in response to
hypoxia in Ethiopians [22].
However, Ethiopians had higher carbon dioxide levels (Table 1),
and increased cerebral reactivity to carbon dioxide—both of
which would likely promote increased cerebral blood flow,
increasing oxygen delivery to the brain. The seemingly paradox-
Figure 4. Symptoms (Signs) Number for CMS scores in the
Peruvian Andes (4338 m. Peru) and Tibetan plateau (4450 m.
Himalaya): 1-SaO2_ 2SD below normal for altitude; 2-Breathlesness,
palpitations; 3-Sleep disturbances; 4-Cyanosis of lips, face or fingers; 5-
dilated veins; 6-Paresthesias in fingers and/or toes; 7-Tinnitus; 8-Hb_2SD
above normal for altitude; 9-Headache. *Denotes significant differences.
In the Peruvian Andes the % of subjects having: sleep disturbances,
paresthesias, tinnitus, high hemoglobin and headache were significant-
ly higher*. Both populations were scored using an internationally
accepted scoring system ($12=CMS)[11].
doi:10.1371/journal.pone.0002342.g004
Figure 5. Expression signatures of a subset of genes examined in Ethiopians, Himalayans and Andeans. Comparisons at altitude (left)
and in normoxia (right), same (control) subjects in each ethnic group. Note the lack of change in expression signatures with normoxia in the
Ethiopians except for (PDP1, P,0.04). In Himalayans none of the gene expressions were changed by normoxia. No differences in molecular signatures
between the Andean study groups (CMS and controls) except significant differences by location (normoxia in Lima). There were significant decreases
in expression at altitude for most genes, except for HPH1, EPO and HPH2 in Andeans; VEGFC was not assayed in Andeans at low altitude. The genes
were: #4-VEGFC; #8-PDK1; #10-EPOR; #11-PDP1; #14-PDK2; #17-HPH1; #18-EPO; #19-HPH2.
doi:10.1371/journal.pone.0002342.g005
Figure 6. Hyperoxia in a tent at 4450 m. on the Tibetan
plateau, near Korzok village in Ladakh, India. The subjects were
exposed to hyperoxia for 1 hour. Note the venous catheters in place on
the forearms to allow the drawing of blood for the post hyperoxia
samples. This maneuver resulted in significant changes in gene
expression in white blood cells.
doi:10.1371/journal.pone.0002342.g006
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highlanders might therefore be advantageous to survival in the
mountains if the pattern of carbon dioxide sensitivity of the
cerebral circulation promotes better perfusion of the brain in
Ethiopians when compared to Andeans [25].
Our Ethiopian subjects also lacked acute ventilatory responses
to changes in PO2 at low and high altitude [25,26].We interpreted
this as indicating a survival advantage to altitude life involving
anaerobic metabolism; advantageous in the highlands.
In the Himalayans the cerebral blood flow responses were
similar to those we found in Ethiopians. They too have higher
responses to CO2 than those reported for sea level subjects and
their cerebral circulation is insensitive to hypoxia [27]. Moreover,
we found also a blunted hypoxic ventilatory response and
suggestions that other mechanisms in addition to hypoxia induced
increases in ventilation, determine adaptation to ‘‘high-life’’ in the
Himalayas [28].
In healthy sea-level individuals adaptive responses to hypoxia
include increased production of vascular endothelial growth
factors and other angiogenic cytokines [29]. Such responses are
also found in Andeans and especially in those with CMS, where
expression levels are very high when compared to sea level
Peruvians [30]. We now find that well-adapted Ethiopians have
even higher expression levels of these factors, which are known to
promote tissue perfusion and better oxygen delivery. One key
molecule, HIF-1 (hypoxia inducible factor-1), controls the
expression of hundreds of genes, including the VEGFs and other
angiogenic cytokines [29].
Here and in our previous studies we examined only white cells
(WBC). Clinically, Andeans and Himalayans show evidence of
vascular proliferation in the skin and conjunctivae [31]. These
clinical signs were not present in our Ethiopian subjects. Thus it is
conceivable that the angiogenic response to ambient hypoxia in
Andeans and Himalayans affects primarily tissues such as the skin
and conjunctivae, which does not boost oxygen delivery to vital
tissues such as the brain; but it favors vital tissues, including the
cardiovascular system, in the well-adapted East Africans; perhaps,
a ‘‘tissue-specific’’ adaptation found only on the East African high
altitude plateau.
HIF plays an important role in the induction of VEGF in
response to hypoxia. However, induction of VEGF by hypoxia has
recently been found to be also independent of HIF [32]. Instead,
the transcriptional coactivator PGC-1a (peroxisome –proliferator-
activated receptor-c coactivator-1a) functions as a crucial
regulator of mitochondrial function in response to hypoxic stress.
Thus another adaptive strategy for human survival in chronic
hypoxia could involve non-HIF dependent induction of VEGF
and other angiogenic factors.
The insensitivity to hypoxia in Ethiopians and Himalayans,
which we found in our previous physiologic studies, is now
matched to an insensitivity in their molecular signatures to acute
changes in blood oxygen tension.
Environmental challenges including hypoxia, which disturb
homeostasis, can lead to disease onset or accelerated aging. These
challenges are continuously met by changes in the biology of
organisms. Proteostasis, the maintenance of cellular protein
function, in the face of external and internal stresses is a key
mechanism in the quest to counteract perturbations of the
proteome (the proteins found in cells) [33].
There are numerous proteins that help organisms handle stress.
Prominently, the heat–shock factors (HSF) which are also
upregulated by hypoxic stress [34]. Some HSFs have found
clinical utility in preventing hypoxic damage in neurodegenera-
tions, cardiovascular, cerebrovascular and pulmonary diseases.
And stimulating HSF has found application in experimental
Parkinson’s disease a disorder associated with ROS production
[35]. By extension, increasing PDPs and PDK in chronic hypoxia
might find application in hypoxia-associated diseases in clinics at
sea level.
The confluence of results from molecular studies, physiologic
investigations and clinical experience in Andeans, Ethiopians and
Himalayans, suggests that further studies of these experiments of
nature might soon find clinical utility at sea level.
Methods
Design
For an explanation of abbreviations see glossary of terms (Text
S1).
A cross-sectional study was performed in Peru in three groups;
high altitude natives with CMS; high altitude controls, and sea
level people without high altitude ancestry. Lack of altitude
ancestry was defined as absence of parents and grandparents
native to the high Andes. Ten subjects were recruited in each
highland group and 20 at sea level. The groups were matched by
age and sex. The protocol was approved by the Ethics Committee
of Cayetano Heredia University in Lima, Peru with Professor Dr.
Luis Huicho MD, Universidad Nacional Mayor de San Marcos,
Lima, Peru, as principal investigator.
A similar cross-sectional study was performed in Ethiopia on 8
high altitude native men born and resident in the Simen Mountain
National Park, they were matched by age with the Peruvian
subjects. The study was approved by the Ethiopian government
and local research ethics committees with Dr. Guta Zenebe,
Professor of Neurology, Addis Ababa University, School of
Medicine and the Yehuleshet Higher Clinic, Addis Ababa, as
principal investigator. (Approval RDHE/52-59/05 dated 31
January 2005, signed Yemane Teklai (Dr.), Head, Health
Department and secretary National Ethiopian Research Council;
NERC). All groups were studied at their native high altitudes and
at low altitude in normoxia.
On the Tibetan plateau, in Ladakh, we obtained IRB approval
from the Ladakh Institute of Prevention (For the Study of
Environmental, Occupational, Life-Style related and High
Altitude Diseases) Dr. Tensing Norboo, Honorary Secretary of
the Institute, as principal investigator, dated April 15 2006.
Because of the impossibility of taking Tibetans off the plateau to
sea level in reasonable time we studied our subjects in their native
environment and after 1 hour of hyperoxia at the same altitude.
A written informed consent was obtained from each subject in
their native languages.
All studies were performed in accordance with the Declaration
of Helsinki (2002) of the World Medical Association.
Inclusion criteria. Peruvian high altitude subjects were
included providing they were native to and resident in Cerro de
Pasco Peru, altitude 4338 m and did not drink herbal infusions
that might reduce red cell mass; a frequent self administered
remedy for CMS. We also included a matched group of subjects
permanently resident at sea level in Lima without high altitude
ancestry.
Ethiopian high altitude subjects were included providing they
were permanent residents and natives of Chennek village situated
at 3662 m altitude in the Simen Mountain National Park,
Ethiopia.
Himalayan subjects were included if they were natives of
Korzok village altitude 4450 m. in Ladakh, India.
Exclusion criteria. We excluded subjects with significant
acute or chronic clinical conditions, or those that had visited
Hypoxia Mountains
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Peruvian subjects were examined in Cerro de Pasco and in Lima
by a senior Peruvian physician (LH). All Ethiopians were
examined by 3 Ethiopian physicians, who accompanied us from
Addis Ababa, to exclude disorders that might confound gene
expression.
Himalayan subjects were examined by 2 physicians from Leh,
Ladakh (TN and DD) who accompanied us to Korzok and by one
of us (OA) with the assistance of the local physicians.
Study procedures
High altitude Peruvian subjects were studied in Cerro de Pasco
first, and then they were transferred to Lima (150 m.) in
approximately 6 hours by bus. Sea level natives were studied in
Lima.
Ethiopians were first studied near their permanent high altitude
residence. They were then transferred to low altitude. It took
approximately 12 hours to arrive by truck in the Tekeze River
Gorge (794.). A clinical history and results of physical examination
and arterial oxygen saturation (pulse oximetry (SaO2) were
recorded. The medical history, in Peru, included current and
past diseases, use of cytotoxic drugs or herbal infusions for
reducing polycythemia, ‘‘maca’’ (a plant protein supplement
frequently used in Peru, containing numerous plant sterols), and
history of descent to altitudes below 2000 m.
A chronic mountain sickness score (CMS-sc) was obtained for
each high altitude subject at the high altitude locations in Peru,
Ethiopia and in Korzok village using an internationally accepted
scoring system. A score of $12 is considered to indicate CMS
[11].
Venous blood samples were taken for hemoglobin and
hematocrit determination, and for RNA assays. Hemoglobin was
determined by spectrophotometry and hematrocrit by a standard
capillary technique. At sea level, blood was taken from high
altitude subjects within 1 hour after arrival at Lima. In Ethiopian
subjects, venous blood samples were obtained the morning after
arrival (,12 hours of normoxia).
The Himalayans were studied first in ambient air at 4450 m.
and then after exposure for 1 hour to hyperoxia at the same
altitude (Fig. 6). Blood samples were obtained before and after
1 hour of hyperoxia.
We made our subjects hyperoxic entering them into the
protocol at 5–10 min intervals. As each subject was seated in
our research tent, a 22 G indwelling intravenous catheter was
inserted into a vein in the dorsum of the hand or forearm and
taped in place. Blood was drawn and immediately transferred to
appropriate tubes for later RNA analysis. The tape securing the
catheter was labeled with subject identification number, test tube
identification, and time of blood sampling. The intravenous
catheter was then flushed with normal saline and capped. Subjects
immediately took their place in a semicircle surrounding the single
K-size O2 tank and had a highly efficient [36] sequential gas
delivery oxygen mask (Hi-Ox
80 ViasysHealthCare, Yorba Linda
CA, USA) placed on their face [37] (Fig. 6). Oxygen flow was
adjusted such that end-tidal PO2 was between 100 and
110 mmHg. The O2 mask of each succeeding subject was
connected in a branching fashion to the O2 tank by using a 3-
way tubing connector. With each succeeding branching of the
tubing, the gas flow from the tank was increased and the end-tidal
PO2 for each subject was re-checked. This was continued until a
maximum of 8 subjects were being administered O2. After one
hour a second set of blood samples was drawn and new subjects
were entered into the hyperoxia part of the protocol. This
experimental set-up required only 3 investigators, one to insert
venous cannulae and draw control blood samples; one to adjust
the gas flows to the Hi-Ox
80 and confirm end tidal values; and one
to draw the blood samples at the conclusion of the hyperoxic
period. The average O2 flow per subject was about 0.5 L/min.
About one third of the O2 tank was consumed during the
experiment.
Quantitative real-time PCR
The total RNA of human white blood cells was extracted using
the PAXgene Blood RNA kit (Qiagen, Germany) following the
manufacturer’s protocol. One microgram (1 mg) of total RNA was
reverse transcribed into first-strand cDNA using the RETROscript
reverse transcriptase kit and oligo dT primers (Ambion, TX)
according to the manufacturer’s protocols. One microliter (1 ml) of
cDNA from the reverse transcriptase reaction was used as the
template for quantitative real-time PCR reaction with a final PCR
reaction volume of 25 ml, with the 59 and 39 gene specific PCR
primer concentrations at 100 nM each. PCR primers were
designed using Primer3 software (Whitehead Institute, MIT,
MA) according to the coding sequences of each gene. Quantifi-
cation of mRNA expression was performed (in triplicate) using the
SYBR Green SuperMix (BioRad, CA) and a 2-step PCR reaction
procedure, performed on the MyiQ Single Color Real-Time PCR
Detection System (BioRad, CA). In brief, after the initial
denaturation at 95u C for 3 min, 45 cycles of primer annealing
and elongation were conducted at 58u C for 45 seconds, followed
by denaturation at 95u C for 10 s. Fluorescent emission data were
captured, and mRNA levels were quantified using the threshold
cycle value. To compensate for variations in input RNA amounts
and efficiency of reverse transcription, data for each target gene
mRNA of each sample were normalized by reference to the data
obtained for the house keeping HPRT (GenBank accession no.
X62085) determined from the same sample. Each real-time PCR
assay was repeated twice.
Statistical methods
Gene expression data were log transformed to obtain symmetric
distributions for analysis and for graphical purposes. Comparison
of gene expression values between the two altitudes were by paired
t-tests. The gene expression variables that best predicted the CMS
classification of 10 Cerro de Pasco subjects with CMS (CMS
score.=12) and 10 Cerro de Pasco controls were obtained by
considering 1 and 2 variable models in stepwise and ‘‘all subsets’’
logistic regression, sensitivity and specificity using median cut
scores, and the effect sizes (standardized beta) in univariate and
bivariate logistic regressions at sea level (Lima) and at altitude
(Cerro de Pasco, 4338m.). The best two gene model using
expressions at sea level (Lima) was LDHA based on sensitivity
(90%) and specificity (100%) and PDP2 based on effect size
(standardized beta) in logistic regression. Since LDHA was not
measured at high altitude (Cerro), PDK3 was used based on
having the highest correlation with LDHA at Lima. The ‘‘niche’’
scatter plots show the two predictor genes selected as best at each
altitude (Fig. 1).
The impact table is constructed using CMS scores as a
continuous variable and consists of the effect sizes (standardized
beta) for each gene in univariate linear regression in the first
columns, the effect sizes for each gene adjusting for the best
univariate predictor (PDP2 at both altitudes) in the middle
columns, and the residual effect size of PDP2 adjusting for each of
the other genes in the final columns (Table 2,3). In addition to the
comparison among high altitude groups, the Lima control subjects
are compared to the high altitude control group, while in Lima
(Fig. 1).
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(Fig. 2, Table 4, 5).
The log transformed gene expressions for the Ethiopian subjects
(n=8) for the 8 genes measured in common with the 2 other high
altitude populations and Lima control subjects are compared as
line graphs (signatures) as a function of the gene number (in
arbitrary order) (Fig. 5). Comparison between altitudes is by paired
t-tests and between groups by unpaired t-tests.
Methodological Constraints
We studied our subjects in the field in 3 continents over a period
of 3 years. Strict laboratory procedures were, usually, unattain-
able. Although larger numbers of subjects in each study group
were desirable these could not be assembled because of time
limitations at altitude for sea level researchers and especially
because molecular studies were combined with physiologic and
clinical evaluations of the same individuals.
The research station of the Universidad Peruana Cayetano
Heredia in Cerro de Pasco, Peru maintains a list of CMS patients
and controls. We used this list to recruit our subjects in Peru.
Because women are protected from CMS until the menopause the
list contains mainly men. Thus, the results of our initial Peruvian
study had unavoidable gender bias. Subsequently, the gender bias
imposed in Peru constrained our selection of subjects in Ethiopia
and the Himalayas.
The geography in the 3 continents precluded exact matching of
altitudes in each location. The choice of our research sites was also
influenced by political expediency, safety issues and ease of access.
In previous field studies we found that exposure to 1 hour of
normoxia at sea level was sufficient to change gene expression in
white cells. This, partly, inspired the design of our study in the
Himalayas where 1 hour of hyperoxia proved sufficient to change
some, but not all, gene expressions without a change in location.
We were encouraged that our method was effective because this
manipulation (Fig. 6) led to significant changes in gene expression
levels in 7 of 20 genes assayed in Himalayan CMS patients (PDK3,
PDK4, PDP1, PDP2, PDHE1A1, HIF1b, and HPH2), in 3 genes
(PDK3, PDK4, and PDP1) when all subjects were considered as a
group, but no changes in expression levels in Himalayan control
subjects.
Our analyses of Ethiopian gene expression were limited by the
vagaries of transport, facilities and access to laboratory personnel,
typical of field studies. Thus, only minute quantities of a small
subset of genes were eventually available for comparison between
the 3 high altitude populations.
In Ethiopia and Peru, the travel time necessary to achieve
normoxia varied greatly. Nevertheless, significant changes in
expression of hypoxia related genes were found in Peru. The
Ethiopians, though spending the longest time in normoxia, failed,
mostly, to show measurable changes in their gene expression
induced by descent.
The number of subjects was small; we emphasize this study is
preliminary rather than conclusive. But the results are suggestive
and consistent enough with physiologic and epidemiologic studies
to warrant further investigation of these altitude populations.
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